Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep ...
Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering ...
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) --. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization ...
In recent trading, Vivos Therapeutics Inc (VVOS) stock price has shown some volatility, fluctuating 4.41% over the last five trades and 8.57% over the past 30 trades. This represents a notable shift ...
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing ...
Vivos Therapeutics, Inc. (VVOS), a medical device and technology company, announced on Thursday that it has inked a deal with ...
Vivos Therapeutics is a pioneering medical device and technology company focused on addressing sleep-related breathing disorders (SRBDs), particularly obstructive sleep apnea (OSA). Their flagship ...
Vivos Therapeutics shares surged 47.50% to close at $4.13, after hitting an intraday high of $5.95 and a low of $3.02. The ...
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent ...
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...